Goldschmidt RH, Dong BJ. Treatment of AIDS and HIV-related conditions—1997. J Am Board Fam Pract 1997;10:144–67.
Centers for Disease Control. 1993 Revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR 1992;41 RR-17:1–19.
Public Health Service statement on management of occupational exposure to human immunodeficiency virus, including considerations regarding zidovudine postexposure use. MMWR 1990;39 RR-1:1–14.
Centers for Disease Control and Prevention. Update: provisional Public Health Service recommendations for chemoprophylaxis after occupational exposure to HIV. MMWR 1996;45:468–72.
Centers for Disease Control. Public Health Service guidelines for counseling and antibody testing to prevent HIV infection and AIDS. MMWR 1987;36:509–15.
Goldschmidt RH, Legg JJ. Counseling patients about HIV test results. J Am Board Fam Pract 1991;4:361–3.
Centers for Disease Control. Tuberculosis and human immunodeficiency virus infection: recommendations of the Advisory Committee for the Elimination of Tuberculosis (ACET). MMWR 1989;38:236–8, 243–50.
Centers for Disease Control. Purified protein derivative (PPD)-tuberculin anergy and HIV infection: guidelines for anergy testing and management of anergic persons at risk of tuberculosis. MMWR 1991;40 RR-5:27–33.
Carpenter CC, Fischl MA, Hammer SM, et al. Antiretroviral therapy for HIV infection in 1996: recommendations of an international panel. International AIDS Society—USA. JAMA 1996;276:146–54.
BHIVA Guidelines Co-ordinating Committee. British HIV Association guidelines for antiretroviral treatment of HIV seropositive individuals. Lancet 1997;349:1086–92.
Centers for Disease Control and Prevention. USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus: a summary. MMWR 1995;44 RR-8:1–34.
Grunfeld C, Feingold KR. Metabolic disturbances and wasting in the acquired immunodeficiency syndrome. N Engl J Med 1992;327:329–37.
Horsburgh CR Jr. Mycobacterium avium complex infection in the acquired immunodeficiency syndrome. N Engl J Med 1991;324:1332–8.
Berger TG, Obuch ML, Goldschmidt RH. Dermatologic manifestations of HIV infection. Am Fam Physician 1990; 41:1729–42.
Cohen PR, Grossman ME. Recognizing skin lesions of systemic fungal infections in patients with AIDS. Am Fam Physician 1994;49:1627–34.
Holland GN, Tufail A. New therapies for cytomegalovirus retinitis. N Engl J Med 1995;333:658–9.
Glatt AE, Anand A. Thrombocytopenia in patients infected with human immunodeficiency virus: treatment update. Clin Infect Dis 1995;21:415–23.
Miller R. HIV-associated respiratory disease. Lancet 1996; 348:307–12.
Masur H. Prevention and treatment of Pneumocystis pneumonia. N Engl J Med 1992;327:1853–60.
Consensus statement on the use of corticosteroids as adjunctive therapy for Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome: the National Institutes of Health-University of California Expert Panel for Corticosteroids as Adjunctive Therapy for Pneumocystis carinii pneumonia. N Engl J Med 1990;323:1500–4.
Centers for Disease Control. Initial therapy for tuberculosis in the era of multidrug resistance: recommendations of the Advisory Council for the Elimination of Tuberculosis. MMWR 1993;42 RR-7:1–8.
Legg JJ. Women and HIV. J Am Board Fam Pract 1993;6:367–77.
Simpson DM, Tagliati M. Neurologic manifestations of HIV infection. Ann Intern Med 1994;121:769–85.
Newton HB. Common neurologic complications of HIV-1 infection and AIDS. Am Fam Physician 1995;51:387–98.
Saag MS, Powderly WG, Cloud GA, et al. Comparison of amphotericin B with fluconazole in the treatment of acute AIDS-associated cryptococcal meningitis. N Engl J Med 1992;326:83–9.
Luft BJ, Hafner R, Korzun AH, et al. Toxoplasmic encephalitis in patients with the acquired immunodeficiency syndrome. N Engl J Med 1993;329:995–1000.
Connor EM, Sperling RS, Gelber R, et al. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. N Engl J Med 1994; 331:1173–80.
Centers for Disease Control and Prevention. Recommendations of the US Public Health Service Task Force on the use of zidovudine to reduce perinatal transmission of human immunodeficiency virus. MMWR 1994;43 RR-11:1–20.